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Abstract
Background: The metabolic syndrome is associated with increased vascular disease risk. We
evaluated two carotid ultrasound measurements, namely intima media thickness and total plaque
volume, in a Canadian Oji-Cree population with a high metabolic syndrome prevalence rate.
Methods: As part of the Sandy Lake Complications Prevalence and Risk Factor Study, 166 Oji-
Cree subjects (baseline metabolic syndrome prevalence, 44.0%, according to the National
Cholesterol Education Program Adult Treatment Panel III guidelines) were examined using a high-
resolution duplex ultrasound scanner.
Results: Image analysis showed that mean intima media thickness was elevated in subjects with the
metabolic syndrome (818 ± 18 vs 746 ± 20 μm), as was total plaque volume (125 ± 26 vs 77.3 ±
17.0 mm3). However, after adjustment for age and sex, the differences were significant only for
intima media thickness (P = 0.039). Furthermore, a significant trend towards increased intima media
thickness was observed with increasing numbers of metabolic syndrome components: mean intima
media thickness was highest among individuals with all five metabolic syndrome components
compared to those with none (866 ± 55 vs 619 ± 23 μm, P = 0.0014). A similar, but non-significant
trend was observed for total plaque volume.
Conclusion: This is the first study of the relationship between the metabolic syndrome and two
distinct carotid ultrasound traits measured in the same individuals. The results suggest that
standard intima media thickness measurement shows a more consistent and stronger association
with the metabolic syndrome than does total plaque volume.
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Background
The metabolic syndrome (MetS) is linked to increased lev-
els of vascular damage [1], cardiovascular morbidity and
cardiovascular mortality [2-4]. A survey of the most recent
evidence estimated that cardiovascular disease risk is
increased ~2-fold in both men and women with MetS [2].
Non-invasive carotid ultrasound techniques can poten-
tially be used to test the validity of this relationship at a
much earlier pre-clinical stage. Furthermore, these surro-
gate measurements of cardiovascular disease may assess a
patient's risk and be used in the evaluation of novel treat-
ments [5].
The commonly used measurement to assess carotid
"atherosclerosis" is intima media thickness (IMT).
Recently, however, newer measurements such as assess-
ment of plaque area or total plaque volume (TPV) have
been suggested to represent a potentially more powerful
approach, since these measurements in higher dimen-
sions evaluate plaque burden in the carotid system and
hold great sensitivity and discrimination [6-8]. IMT and
TPV, however, are not interchangeable. Their correlation
is only moderate (r < 0.7) and these different ultrasound-
derived measures of carotid artery morphology likely rep-
resent distinct attributes of atherosclerosis [9,10]. As more
research is needed to provide a complete understanding of
how these ultrasound traits relate to cardiovascular dis-
ease stages and endpoints we have evaluated two carotid
ultrasound measurements, namely IMT and TPV, in a
Canadian Oji-Cree population with one of the highest
MetS prevalence rates in the world [11].
Methods
Study subjects
All subjects in the current study had formerly been partic-
ipants in the original 1993–1995 Sandy Lake Health and
Diabetes Project [12]. The Oji-Cree community of Sandy
Lake, Ontario, is located ~2000 km northwest of Toronto,
in the subarctic boreal forest of central Canada. 728 mem-
bers of this community (72% of the total population),
≥10 years of age, participated in the original survey.
Detailed information on demographics, dietary habits,
and physical fitness of the study participants has been pre-
viously reported [13-15]. In a separate study initiated in
2001, the Sandy Lake Complications Prevalence and Risk
Factor Study [16], 278 subjects (51.1% with diabetes)
who were free of coronary heart disease had ultrasound
assessment of the carotid arteries. The studies were
approved by the Sandy Lake First Nation Band Council
and the University of Toronto Ethics Review Committee.
For this study, 166 subjects were selected on the basis of
having both a complete set of data for MetS diagnosis
from the original survey and carotid ultrasound measure-
ments from the follow-up study. Signed informed consent
was obtained from all participants.
Clinical characteristics and biochemical analysis
Body weight, height, waist circumference, and blood pres-
sure were measured by standardized procedures [12].
Hypertensive individuals were defined as subjects having
increased blood pressure (≥130 mmHg systolic and/or
≥85 mmHg diastolic) or on antihypertensive drug treat-
ment. Measurements of fasting blood analytes, including
triglycerides, glucose, and lipoproteins were performed as
described [12].
Metabolic syndrome (MetS) case definition
According to the National Cholesterol Education Program
Adult Treatment Panel III (NCEP ATP III) criteria [17],
MetS was identified if a subject had ≥3 of: 1) increased
waist circumference (>102 cm [>40 inches] for men, >88
cm [>35 inches] for women); 2) elevated plasma triglycer-
ides (≥1.69 mmol/L [≥150 mg/dL]); 3) low plasma HDL
cholesterol (<1.04 mmol/L [<40 mg/dL] for men, <1.29
mmol/L [<50 mg/dL] for women); 4) increased blood
pressure (≥130 mmHg systolic and/or ≥85 mmHg diasto-
lic) or on antihypertensive drug treatment; and 5)
impaired fasting glucose (≥6.1 mmol/L [≥110 mg/dL]).
Ultrasound examination
Subjects were examined using a high-resolution duplex
ultrasound scanner HDI 5000 equipped with Sono-CT
compound imaging and a L12-5 transducer (Advanced
Technology Laboratories, Bothell, Washington) that had
been flown to the community and housed within the Dia-
betes Research Center. Common carotid ultrasound
images for all participants were gathered over a 4-week
period, and from this data, intima-media thickness (IMT),
total plaque area (TPA), and total plaque volume (TPV)
measurements were determined [9,10]. TPA was strongly
correlated with TPV in these subjects (r  = 0.921, P  <
0.0001) and thus for simplicity, only TPV measurements
were used. The correlation between IMT and TPV was
0.467 (P < 0.0001).
IMT measurement
IMT was determined as previously described [9,10].
Briefly, a single observer, blinded to subjects' vascular risk,
measured combined thickness of intima and media of the
far wall of both common carotid arteries. Images were
recorded from an anterolateral longitudinal view. The still
images were analyzed using computerized edge-detection
software (Prowin™) [18]. Using a step-wise algorithm,
conditional sets of "edges" (consisting of lumen-intima
and media-adventitia echoes) were located within the
image and then tested for "edge strength", with the subse-
quent deletion of weak edge points. Once all acceptable
edge points were identified, boundary gaps were filled by
linear interpolation. The distance between lumen-intima
and media-adventitia boundaries was then measured to
calculate IMT. Mean IMT was computed from 120 meas-Cardiovascular Ultrasound 2006, 4:28 http://www.cardiovascularultrasound.com/content/4/1/28
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urements over a 10 mm span ending 5 mm proximal to
the transition between the common carotid and bulb
regions. Intra- and inter-operator coefficients of variation
were 3.0 and 3.1%, respectively, and intra- and inter-oper-
ator intraclass correlations were both 0.97.
TPV measurement
TPV was determined as previously described [9,10].
Briefly, 3D ultrasound images were acquired using a free-
hand scanning system and analyzed with L3Di visualiza-
tion software (Life Imaging Systems Inc., London,
Ontario). Plaque volumes were measured using manual
planimetry: each 3D image was 'sliced' transversely at an
inter-slice distance of 1 mm, moving from one plaque
edge to the other. Plaque boundaries were traced using a
mouse driven cross-haired cursor. Slice areas were
summed and multiplied by inter-slice distance to calcu-
late plaque volume. For this analysis, TPV was defined as
the sum of all plaque volumes between the clavicle and
angle of the jaw for both carotids, including areas from
both the common and internal carotid systems. Intra- and
inter-operator coefficients of variation were 6.5 and 6.9%,
respectively, and intra- and inter-observer reliability were
0.87 and 0.91, respectively [19].
Statistical analysis
SAS version 8.2 (SAS Institute, Cary, North Carolina) was
used for all analyses. The FREQ procedure was used to
determine the frequencies of categorical variables. Differ-
ences in proportions were tested by χ2 analysis. The mean
± standard error (SE) of continuous variables describing
the demographic and laboratory characteristics for those
with and without MetS were analyzed by ANOVA, using
the general linear model, adjusting for age and sex.
Plasma triglycerides were not normally distributed and
were log transformed. Significance was calculated from
type III sums of squares, which are most appropriate for
unbalanced study designs and report significance after all
covariates are taken into account. Differences in IMT and
TPV were also analyzed using the general linear model,
adjusting for age and sex. IMT and TPV were both signifi-
cantly non-normal in this dataset and thus were trans-
formed using the inverse of IMT and the square root of
TPV. Pair-wise differences in IMT or TPV according to the
number of MetS components were compared using the t-
statistic for least squares means from ANOVA. Statistical
significance was taken at nominal P < 0.05 for all compar-
isons. Transformed values were used for statistical com-
parisons, but untransformed values are shown in the
tables and figures.
Results
Demographics, clinical and biochemical features based on 
MetS
Table 1 shows the demographic and metabolic character-
istics of Oji-Cree subjects with and without MetS. MetS
prevalence was 44.0% (73/166) according to the NCEP
ATP III criteria. Those with MetS were significantly older
than those without MetS (P = 0.0019); no differences were
found with respect to sex and smoking habits. As
expected, clinical and biochemical measurements that
contributed to the MetS definition, such as waist circum-
ference, HDL cholesterol, triglycerides, blood pressure,
and fasting glucose were significantly different between
subjects with and without MetS. In addition, other traits
not considered to be a part of the official MetS definition,
such as BMI (body mass index), total cholesterol and
Table 1: Demographic and clinical features of Oji-Cree study group
Characteristic MetS present N = 73 MetS absent N = 93 P-value adjusted for age and 
sex
age (years) 42.2 ± 1.6 34.8 ± 1.6 0.0019
male (%) 35.6 43.0 NS (0.33)
current smokers (%) 13.9* 16.3† NS (0.86)
BMI (kg/m2) 31.3 ± 0.5 27.4 ± 0.5 <0.0001
waist (cm) 104 ± 1 92.9 ± 1.2 <0.0001
hypertensive (%) 54.8 18.3 <0.0001
antihypertensive treatment (%) 19.2 5.4 0.017
total cholesterol (mmol/L) 5.21 ± 0.10 4.38 ± 0.08 <0.0001
HDL cholesterol (mmol/L) 1.09 ± 0.03 1.27 ± 0.02 <0.0001
triglycerides (mmol/L) 2.36 ± 0.11 1.24 ± 0.05 <0.0001
TC:HDL ratio 4.99 ± 0.15 3.54 ± 0.09 <0.0001
fasting glucose (mmol/L) 9.48 ± 0.54 6.34 ± 0.30 <0.0001
diabetes (%) 67.1 17.2 <0.0001
IGT (%) 8.2 14.0 NS (0.72)
*N = 72, †N = 92
Data are means ± SE, unless otherwise stated.
Abbreviations: IGT, impaired glucose tolerance; NS, not significantCardiovascular Ultrasound 2006, 4:28 http://www.cardiovascularultrasound.com/content/4/1/28
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TC:HDL ratio were also elevated in the MetS subjects (P <
0.0001).
Relationship with carotid atherosclerosis
Carotid ultrasound measurements were gathered 7 years
following the baseline MetS diagnosis (Figure 1). As
shown in Table 2, values for both mean IMT and TPV were
elevated in those with MetS. However, after adjustment
for age and sex, the observed differences were significant
only for the evaluation of IMT (818 ± 18 [MetS present] vs
746 ± 20 μm [MetS absent], P = 0.039).
Evaluations based on the number of MetS components
present showed a significant trend towards increased IMT
with increasing numbers of MetS components (Figure 2).
Those with all five MetS components had the greatest IMT
while those with none of the components had the small-
est IMT (866 ± 55 vs 619 ± 23 μm, P = 0.0014). Each pair-
wise comparison of increasing MetS component number
was significant. In contrast, for TPV, no significant differ-
ences were observed between individuals with any
number of MetS components and those with none (Figure
3).
Discussion
We found: 1) elevated carotid IMT for subjects with MetS
in comparison to those without MetS (P = 0.039); 2) no
significant difference in carotid TPV for subjects with
MetS, adjusting for age and sex; and, 3) a trend towards
increasing IMT with increasing numbers of MetS compo-
nents. The results suggest that IMT has a stronger and
more consistent relationship with MetS than does TPV.
Our results are consistent with previous studies of IMT
which have also found a significant association between
increased carotid artery thickening and MetS diagnosis. In
the largest study to date, the Atherosclerosis Risk in Com-
munities (ARIC) study (N = 12,178), MetS was signifi-
cantly associated with both an increased risk of coronary
heart disease and also with increased IMT. The observed
difference between those with and without MetS was rela-
tively small (747 vs 704 μm), but highly significant (P <
0.0001), even after adjustment for age, sex, and race/study
[20]. Similarly in an Austrian study (N = 1,588), IMT was
found to be significantly higher in subjects with MetS (P <
0.0005) [21]. The observed difference in IMT between
those with and without MetS was more pronounced in
females than in males, indicating a potentially stronger
relationship between MetS and atherosclerosis in females
[21].
One distinctive feature of our study was the relatively
younger age of our Oji-Cree sample, which may be
affected by a lesser degree of measurable disease progres-
sion. Interestingly we observed a difference in IMT of ~70
μm between those with and without MetS, greater than
Ultrasound images used for the determination of carotid anatomy in a subject with MetS Figure 1
Ultrasound images used for the determination of carotid anatomy in a subject with MetS. The panel on the left shows an image 
of the right carotid artery used to determine intima media thickness (IMT), with the arrows at the far carotid wall showing 
where IMT was determined. The panel on the right shows an image used to determine total plaque volume (TPV), with the 
encircled coloured region defining one of the plaques identified.
IMT = 0.95 mm TPV = 297 mm3Cardiovascular Ultrasound 2006, 4:28 http://www.cardiovascularultrasound.com/content/4/1/28
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the difference observed in the ARIC study, yet similar to
the values observed for the middle-aged females in the
Austrian study. Observing this degree of IMT for subjects
with MetS among the relatively young Oji-Cree collective
is consistent with the high prevalence of both type 2 dia-
betes and coronary heart disease that have been observed
in this population [14,22].
While a significant difference was found for IMT, no sig-
nificant difference was found for TPV between subjects
with MetS and subjects without MetS, although TPV
tended to be greater among subjects with MetS. The
absence of statistical significance following adjustment
for age and sex is undoubtedly related to the small
number of subjects and the proportion of individuals
without measurable plaque (TPV ≤ 0.01 mm3 for 31% of
subjects), but it may also be because of the relative insen-
sitivity of carotid TPV as a surrogate marker for atheroscle-
rosis (i.e. greater intra- and inter- operator variation) or
because patients with MetS have increased IMT rather
than increased plaque. Previous studies have reported that
the correlation between IMT and TPV is only modest (r <
0.7), indicating that these measures likely represent dis-
tinct attributes of atherosclerosis [7,9,10]. This is under-
standable, considering that the measurement of IMT is
based on a single defined location near to the transition
between the common carotid and bulb regions, whereas
the measurement of TPV involves the whole carotid sys-
tem, and thus disparities can arise depending on whether
or not plaque happens to be present in this designated
area. When measured in the same subjects, these ultra-
sound traits have been shown to have distinct relation-
ships with individual risk factors [9], diabetes [7], and
genetic determinants [23,24]. TPV may better reflect the
later stages of plaque formation and the total disease bur-
den, especially among subjects with diabetes [7,9],
whereas IMT, correlating more closely with hypertension
and age [9], may reflect wall hyperplasia or hypertrophy
related to hypertension. This considered, it may be that
IMT would capture vascular disease burden more effec-
tively in MetS-affected subjects, considering that both
systolic and diastolic blood pressure are key components
of the MetS definition.
A limitation of our study and others is the lack of prospec-
tive data to determine the relationship between MetS and
the progression of carotid ultrasound traits. A prospective
Total carotid plaque volume, plotted according to an individ- uals' number of MetS components (mean ± SE) Figure 3
Total carotid plaque volume, plotted according to an individ-
uals' number of MetS components (mean ± SE). All P-values 
for pair-wise differences in TPV were not significant (P > 
0.05).
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Table 2: Carotid ultrasound measurements according to presence or absence of MetS
Trait MetS present N = 73 MetS absent N = 93 P unadjusted P adjusted for age and 
sex
Mean IMT (μm) 818 ± 18 746 ± 20* 0.0008 0.039
TPV (mm3) 125 ± 26 77.3 ± 17.0 0.021 NS (0.64)
*N = 91
Data are means ± SE.
Mean carotid IMT values, plotted according to an individuals'  number of MetS components (mean ± SE) Figure 2
Mean carotid IMT values, plotted according to an individuals' 
number of MetS components (mean ± SE).
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study of 316 Swedish middle-aged men found that IMT
was greater at baseline and also after three years in sub-
jects with MetS, while no significant change was observed
for subjects with no MetS risk factors [25]. Further pro-
spective studies such as these, analyzing the use of ultra-
sound measures for detecting disease progression, would
be potentially valuable for future MetS research.
In addition, it would have been beneficial if our study
evaluated additional, more general populations, to deter-
mine if this pattern of positive association for IMT and no
association for TPV is typical or simply a unique observa-
tion for the Oji-Cree. The Oji-Cree study group was also
not just a typical population, in that the prevalence of dia-
betes was >50% for the MetS subjects. Considering the
distinctiveness of the carotid ultrasound trait measures, it
is indeed highly likely that there will also be distinct rela-
tionships observed depending on the population studied.
Conclusion
Our study of the relationship between MetS and carotid
atherosclerosis has, to the best of our knowledge, evalu-
ated IMT and TPV in parallel, for the first time. For this
study group, the observations show that standard IMT
measurement captures an increased disease burden
among individuals with MetS, while the TPV measure-
ment appears somewhat less strongly related and less
informative. This supports previous reports of increased
carotid ultrasound analytes for persons with MetS, but
additionally, this study indicates that TPV may not be as
valuable a surrogate marker of vascular disease burden in
MetS, though this is likely dependent on the characteris-
tics of the study population.
Ultrasound measurements are, however, only surrogate
markers for risk of arterial occlusion. What would be of
great interest is to know which test correlates more closely
with outcome. This is an important step for future studies.
Though increased TPV was not a significant hallmark for
those with MetS in this study, it still, nonetheless, is a dis-
tinct ultrasound trait which may be shown to be an
important preclinical marker for arterial occlusion risk.
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